Now is a crucial time for the gene therapy field, as the ripple effects of the pioneering first US gene therapy approval are being felt globally, setting new benchmarks and posing unexpected questions.

Gene Therapy for Rare Disorders Europe is the uniquely focused conference that will bring the leaders in in this field together to discuss the critical factors involved in driving commercial success for gene therapies in the complex European landscape.

Take a look at our highlights video from our US meeting earlier this year, to see what you can expect:

Bringing together leading experts from innovative biotechs, large pharma, payers, investors and academics, this conference will present a comprehensive insight into the cutting edge progress of gene therapies combatting rare disease.

Here’s a snapshot of the companies who attended last year:

Pfizer – Shire – Lysogene – BioMarin – Novasep – Horama – Orchard Therapeutics – Avrobio
Genzyme – Astellas – uniQure – Syneos Health – REGENXBIO – Chiesi – TIGET – Syncona
GenSight – GSK – Covance – Bioverativ – Cell Therapy Catapult – Vertex – DAK Gesundheit
MHRA – Vivet – Oxford Genetics – Innovate UK – Gilead – IQVIA – Servier – Rocket Pharma

Request the attendee breakdown from our European and US conferences.

Join your colleagues and accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.